Looks awesome. While the "nearsighted" are only looking at the MRSA skin infection market which is ~300 million, We should be focusing on the entire MRSA "standard-of-care" universe. They can look at $10 pps, I'm focusing on $50 pps. Somehow I really don't think the makers of Linezoid are sleeping all that well these days. tough to lose a billion dollars a year in revenue.
Absolutely. MRSA is a systemic issue. On the Rxlist website (google rxlist mrsa) there are numerous accounts of people applauding how Zyvox saved their lives when they had raging internalized infections. Also, in wikipedia, look up MRSA. Under the clinical trial drugs on deck, Ted is listed (Torezolid)...and given my research the others in dev are near the drug that Ted is.